COVID-19 Respiratory Infection Clinical Trial
Official title:
Efficacy of Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang With Ginseng) on Mild and Moderate COVID-19 Patients: A Multicenter, Prospective, Randomized Controlled Trial
| Verified date | May 2023 |
| Source | University of Medicine and Pharmacy at Ho Chi Minh City |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19 (coronavirus disease 2019). Patients with COVID-19 may experience various clinical manifestations, from no symptoms to critical illness such as severe pneumonia and acute respiratory distress syndrome (ADRS). So far, there is no specific medication for COVID-19; hence, the current available treatments mostly aim at symptoms management and supportive care. From traditional medicine perspective, COVID-19 is classified as warm-disease (Wen-yi). The main points of treatment for COVID-19 in early stage based on traditional medicine perspective are strengthen the Protective Qi (Wei Qi - the body immune system), and restore the balance of Qi, which is vital biological energy to prevent the invasion of external pathogens, including the SARS-CoV-2 virus. The Shen Cao Gan Jiang Tang have including Gan Cao Gan Jiang Tang (GGT) with the addition of Ginseng. This formula is originated from Shang Han Lun (Treatise on Febrile Diseases Caused by Cold) by Zhang Zhong-jing, used to enhance the Protective Qi, treat the early stage of Febrile Diseases, This clinical trial aims to evaluate the efficacy of the Shen Cao Gan Jiang Tang on mild and moderate COVID-19 patients
| Status | Completed |
| Enrollment | 300 |
| Est. completion date | December 25, 2021 |
| Est. primary completion date | December 25, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 64 Years |
| Eligibility | Inclusion Criteria: - From full 18 to 64 years old; - The patient was diagnosed with SARS-CoV-2 infection by RT-PCR confirmation (+) and CT < 30. - Patients classified as mild (acute upper respiratory tract infection): patients infected with SARS-CoV-2 early in the first 5 days from the time of having one of the non-specific clinical symptoms such as fever, cough dry, sore throat, stuffy nose, fatigue, headache, muscle pain, decreased taste, decreased sense of smell. And there are no signs of pneumonia or hypoxia, respiratory rate = 20 times/min, Saturation of Peripheral Oxygen (SpO2) = 96% when breathing air. - Patients classified as moderate (Pneumonia): patients infected with SARS-CoV-2 in the first 10 days from the time of having one of the non-specific clinical symptoms, showing signs of pneumonia (fever, cough, dyspnea, tachypnea >20 breaths/min) and no signs of severe pneumonia, Saturation of Peripheral Oxygen (SpO2) = 93% when breathing air. - Inpatient treatment - Subjects do not use any other medicines with herbal ingredients for underlying conditions or any other purposes; - Voluntary participation in the study by signing an informed consent - Patients who have not been vaccinated or have just received 1 dose of COVID-19 vaccine Exclusion Criteria: - Severe or critical COVID-19 based on the COVID-19 severity scale of Vietnam Ministry of Health; - Chronic obstructive pulmonary disease, kidney failure requiring dialysis or creatinine = 2.0mg/dl through medical history; parenteral or parenteral nutrition, uncontrolled type 2 diabetes (HbA1c > 7%), uncontrolled hypertension (value > 160/100 mmHg), uncontrolled coronary artery disease (new/currently established) requires medication adjustment), heart failure, neurological disease (eg, acute stroke, polyneuritis within 1 month) or mental illness, active tuberculosis, active autoimmune disease; - Have a chronically weakened immune system (AIDS, cancer, undergoing chemotherapy-radiotherapy in the past six months, immunosuppressive disease); - Taking immunosuppressive drugs (e.g., anti-rejection treatment after organ transplant or blood stem cell transplant); - Allergic to products that contain ginseng; - Pregnant or lactating women; - Already participating in another clinical trial; - The patient has received 2 doses of COVID-19 vaccine. |
| Country | Name | City | State |
|---|---|---|---|
| Vietnam | University of Medicine and Pharmacy at Ho Chi Minh City | Ho Chi Minh |
| Lead Sponsor | Collaborator |
|---|---|
| University of Medicine and Pharmacy at Ho Chi Minh City |
Vietnam,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Duration of symptoms of COVID-19 | Time (days) from randomization to symptoms disappear | From Day 1 to Day 21 after randomization | |
| Primary | The severity of the COVID-19 total and individual symptoms | Time (days) from randomization to the relief of total and individual COVID-19 symptoms scores | From Day 1 to Day 21 after randomization | |
| Primary | Rate of progression to disease severity | Number of patients (%) progressed to severe level of COVID-19 severity scale based on the Vietnam Ministry of Health severity scale during the period of the treatment | During inpatient treatment, maximum to Day 21 after randomization | |
| Primary | The time required to meet discharge standards | Time (days) from randomization to get required for a negative real-time polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 or CT > 30 | During inpatient treatment, maximum to Day 21 after randomization | |
| Primary | National Early Warning Score 2 (NEWS2) | Assessed by National Early Warning Score 2 (NEWS2) | During inpatient treatment, maximum to Day 21 after randomization | |
| Secondary | Cycle threshold (CT) | Cycle threshold (CT) values on the COVID-19 RT-PCR test | During inpatient treatment, maximum to Day 21 after randomization | |
| Secondary | Duration of SARS-CoV-2 virus infection | Time (days) from randomization to negative the COVID-19 RT-PCR test | During inpatient treatment, maximum to Day 21 after randomization | |
| Secondary | Mortality rate | The number of deaths (%) caused by COVID-19 | From Day 1 to Day 21 after randomization | |
| Secondary | Number of participants clinically recovered | Number of patients (n) without symptoms of COVID-19 on date of discharge | From Day 1 after randomisation to Day for patients meet discharge criteria | |
| Secondary | Paracetamol/Ibuprofen intake | The number (n) of daily doses of paracetamol/ibuprofen consumed during inpatient | From Day 1 after randomisation to Day for patients meet discharge criteria | |
| Secondary | Safety evaluation | Number of patients (n) that have the side effects due to the decoction based on clinical monitoring | From Day 1 to Day 21 after randomization |